Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.66 |
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629274 | 0.91 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL4629479 | 0.90 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL4629430 | 0.87 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL4627556 | 0.85 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL4629252 | 0.81 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL4627416 | 0.81 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL1578277 | 0.80 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL4628732 | 0.80 | KMT2A (0.66) | NPC1RAB9ASMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL8582841 | 0.79 | NAAA (0.69) | SMN1; SMN2L3MBTL1POLBTDP1ALDH1A1 | |
| SCHEMBL19820079 | 0.78 | MAPK1 (0.62) | SMN1; SMN2L3MBTL1POLBTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | NPC1 140/4885RAB9A 617/4885SMN1; SMN2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.